Make an Inquiry
Accelerating Sjogren Syndrome Drug Development

Sjogren syndrome presents significant therapeutic challenges due to its complex autoimmune pathology and unmet clinical needs. Protheragen stands as a specialized partner in the development of innovative therapeutics for Sjogren syndrome, offering a full spectrum of preclinical drug development services. From target validation and lead optimization to IND-enabling studies, Protheragen integrates deep scientific expertise with advanced technology platforms to drive efficient and rigorous preclinical programs. Our multidisciplinary team leverages cutting-edge in vitro and in vivo models, high-throughput screening, and translational biomarker strategies to ensure robust candidate selection and data-driven decision-making. Protheragen’s operations adhere to the highest standards of regulatory compliance, facilitating seamless progression toward clinical development. With a proven track record in autoimmune disease research and a commitment to scientific excellence, Protheragen is dedicated to accelerating the discovery and development of effective therapies for Sjogren syndrome. Our focused approach empowers partners to advance novel candidates with confidence, ultimately aiming to deliver meaningful therapeutic breakthroughs for patients in need.

What is Sjogren SyndromeTargets for Sjogren SyndromeDrug Discovery and Development ServicesWhy Choose Us

What is Sjogren Syndrome

Sjogren Syndrome is a chronic, systemic autoimmune disorder characterized by the immune-mediated destruction of exocrine glands, primarily the salivary and lacrimal glands. The disease arises from a combination of genetic predisposition, environmental triggers, and dysregulated immune responses, leading to the activation of autoreactive T and B lymphocytes. This process results in the production of autoantibodies, such as anti-SSA/Ro and anti-SSB/La, and cytokine-driven tissue injury, ultimately causing glandular dysfunction. Sjogren Syndrome may occur as a primary condition or in association with other autoimmune diseases, such as rheumatoid arthritis or systemic lupus erythematosus. Clinically, Sjogren Syndrome most commonly presents with persistent dry mouth (xerostomia) and dry eyes (keratoconjunctivitis sicca), but can also involve systemic features like fatigue, arthralgia, and an increased risk of non-Hodgkin lymphoma. Diagnosis is based on a combination of symptoms, objective tests for glandular function (e.g., Schirmer’s test, salivary flow measurement), serological markers (anti-SSA/Ro, anti-SSB/La), and confirmatory minor salivary gland biopsy. Treatment focuses on symptomatic relief and includes muscarinic agonists such as cevimeline and pilocarpine to stimulate glandular secretion, as well as sialogogues like anethole trithione. Management also addresses complications and monitors for systemic involvement.

Launched Drugs

Structure Generic Name CAS Registry Number Molecular Formula Molecular Weight
img-107233-08-9-free-base-anhydrous-cevimeline-hydrochloride-prop-innm-usan cevimeline hydrochloride (Prop INNM; USAN) 107233-08-9 (free base, anhydrous) C10 H17 N O S . Cl H . H2 O 253.789
img-54-71-7-pilocarpine-hydrochloride-usan-banm pilocarpine hydrochloride (USAN; BANM) 54-71-7 C11 H16 N2 O2 . Cl H 244.718
img-532-11-6-anethole-dithiolethioneanethole-trithione anethole dithiolethione; anethole trithione 532-11-6 C10 H8 O S3 240.365

Learn More

Targets for Sjogren Syndrome

Targets in Clinical or Later Phases of Development

Target Name Gene Symbol
Muscarinic Acetylcholine Receptor (mAChR) (nonspecified subtype)
CD80 molecule CD80
CD40 ligand CD40LG
CD86 molecule CD86
Fc gamma receptor and transporter FCGRT
TNF superfamily member 13 TNFSF13
TNF superfamily member 13b TNFSF13B
tyrosine kinase 2 TYK2
TNF receptor superfamily member 13C TNFRSF13C
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta PIK3CD

Key therapeutic targets in Sjogren syndrome (SS) are central to the dysregulated immune pathways underlying the disease. B cell activation and survival are driven by molecules such as Bruton Tyrosine Kinase (BTK), Spleen Associated Tyrosine Kinase (SYK), and Phosphatidylinositol-4,5-bisphosphate 3-kinase delta (PIK3CD), which amplify B cell receptor signaling, promote autoantibody production, and sustain lymphocytic infiltration of exocrine glands. Additional targets like TNFSF13B (BAFF), TNFSF13 (APRIL), and their receptor TNFRSF13C (BAFF-R) are crucial for B cell survival and are upregulated in SS. T cell co-stimulatory molecules, including CD40, CD40LG, CD80, and CD86, facilitate aberrant T-B cell interactions and germinal center formation. Cytokine signaling components such as TYK2 and JAK2 further perpetuate inflammation via the JAK/STAT pathway. Innate immune receptors like TLR7 and TLR8 initiate type I interferon responses, while FCGRT modulates IgG handling and immune complex persistence. These molecular targets offer multiple avenues for therapeutic intervention. BTK, SYK, and PI3Kδ inhibitors, as well as BAFF antagonists, are in various stages of clinical development or approved for related autoimmune conditions, with promising preclinical and translational data in SS. Blockade of T cell co-stimulatory pathways using agents like abatacept (CTLA4-Ig) and anti-CD40LG antibodies is under investigation to disrupt pathological immune cell crosstalk. JAK inhibitors, including baricitinib, target cytokine-driven inflammation and are being evaluated in clinical trials. Modulation of innate immune sensors (e.g., TLR7 antagonists) and FcRn-mediated IgG recycling represents additional emerging strategies. Collectively, these targets not only deepen understanding of SS pathogenesis but also inform the rational design of novel, mechanism-based therapies.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our In Vitro Efficacy Testing Service for Sjogren syndrome accelerates drug discovery by offering comprehensive, high-throughput screening and characterization of therapeutic candidates. Utilizing advanced assay platforms—including FRET, ELISA, chemiluminescent, flow cytometry, and FACS—we evaluate drug efficacy, target engagement, and immune modulation across key disease-relevant biomarkers and pathways. Quantitative parameters such as IC-50, EC-50, Kd, and Ki provide robust data for candidate ranking and optimization. Our expertise ensures precise assessment of mechanism of action and pathway modulation, supporting informed decision-making in preclinical development and enabling the identification of promising therapies for Sjogren syndrome.

Bruton Tyrosine Kinase Cd40 Molecule
Cd80 Molecule Cd86 Molecule
Fc Gamma Receptor And Transporter Janus Kinase 2
Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta Tnf Superfamily Member 13B
Tyrosine Kinase 2

Learn More

Why Choose Us

Choosing Protheragen means partnering with a team that is deeply committed to advancing therapies for Sjogren syndrome through specialized expertise and unwavering professionalism. At Protheragen, our dedicated scientists and clinicians possess extensive experience in Sjogren syndrome research and drug development, ensuring that every project benefits from the latest scientific insights and targeted approaches. Our advanced technology platforms support a comprehensive range of preclinical studies, enabling us to deliver precise and reliable results for our clients. Protheragen has established a strong track record in preclinical drug development, consistently meeting timelines and exceeding expectations for quality and reliability. We adhere to the highest quality standards and maintain strict regulatory compliance throughout every stage of our services, giving our partners confidence in both the process and the outcome. Above all, Protheragen is committed to driving progress in Sjogren syndrome therapeutics, working tirelessly to bring innovative solutions closer to patients in need. By choosing Protheragen, you are selecting a trusted partner dedicated to excellence, integrity, and meaningful scientific advancement in the field of Sjogren syndrome.

FAQs for Our Services

Q: What are the main preclinical research challenges specific to developing drugs for Sjogren syndrome?

A: One of the primary challenges in preclinical research for Sjogren syndrome is the lack of robust and predictive animal models that fully recapitulate the complex autoimmune pathology of the disease. Additionally, heterogeneity in disease presentation among patients complicates the identification of relevant biomarkers and therapeutic targets. Our company addresses these challenges by utilizing a combination of established and innovative animal models, as well as leveraging advanced in vitro systems and biomarker discovery platforms to better mimic the human disease environment.

Q: What are the key regulatory considerations for preclinical drug development targeting Sjogren syndrome?

A: Regulatory agencies such as the FDA and EMA require comprehensive data on safety, pharmacokinetics, and proof-of-concept efficacy before approving clinical trials for Sjogren syndrome therapies. Given the autoimmune nature of the disease, regulators may request additional immunotoxicology studies and long-term safety assessments. Our preclinical services are designed to ensure full compliance with global regulatory guidelines, including preparation of IND-enabling packages and consultation on study design to address disease-specific regulatory expectations.

Q: What technical aspects are critical when conducting preclinical research for Sjogren syndrome?

A: Critical technical aspects include the selection and validation of appropriate animal models (such as NOD mice or genetically engineered models), development of relevant in vitro assays, and the use of sensitive analytical methods to measure biomarkers of glandular dysfunction and systemic autoimmunity. Our team employs state-of-the-art imaging, histopathology, and molecular techniques to provide comprehensive data on drug efficacy and mechanism of action, ensuring translational relevance to human Sjogren syndrome.

Q: What are the typical timeline and cost considerations for preclinical development of drugs for Sjogren syndrome?

A: Preclinical development timelines for Sjogren syndrome drug candidates generally range from 12 to 24 months, depending on the complexity of the compound and required studies. Costs can vary significantly, typically ranging from $1M to $5M, influenced by the extent of efficacy, safety, and biomarker studies needed. Our company offers tailored project management and budgeting to optimize resource allocation, streamline workflows, and minimize delays without compromising scientific rigor.

Q: What are the main success factors in preclinical drug development for Sjogren syndrome?

A: Success in preclinical drug development for Sjogren syndrome hinges on several factors: robust disease modeling, identification and validation of predictive biomarkers, early engagement with regulatory authorities, and a multidisciplinary approach integrating immunology, pharmacology, and toxicology expertise. Our company’s integrated platform and experienced scientific team are dedicated to maximizing the translational potential of your drug candidates, reducing risk, and accelerating the path to clinical development.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © 2025 Protheragen. All rights reserved.